Is Decoy Therapeutics Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Decoy Therapeutics Inc (DCOY) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Decoy Therapeutics Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Decoy Therapeutics Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Decoy Therapeutics Inc?

Muslim investors may consider investing in Decoy Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Decoy Therapeutics Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Decoy Therapeutics Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Decoy Therapeutics Inc updated?

The Shariah compliance status of Decoy Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Decoy Therapeutics Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Decoy Therapeutics Inc?

You can check the latest Shariah compliance status of Decoy Therapeutics Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

DCOY Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: May 01, 2026

Report Source: 2025 Annual Report

Decoy Therapeutics Inc. Stock Analysis DCOY

United States Health Care Nano Cap Report: 2025 Annual

Decoy Therapeutics, Inc. operates as a preclinical-stage biotechnology company. The company is headquartered in Houston, Texas and currently employs 11 full-time employees. The company went IPO on 2015-01-29. The Company’s initial pipeline is focused on respiratory viruses and GI cancers. In parallel, the Company is advancing discovery programs, including multi-virus decoy candidates designed to address overlapping respiratory threats, and cell-based and organoid-level validation of novel G protein-coupled receptor (GPCR)-targeted drug candidates outside of antivirals.

Key Statistics of Decoy Therapeutics Inc (DCOY)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$4.32$4.64

Today's Open

$4.50

Volume

6084.00

P/E Ratio (TTM)

52 Week Range

$4.32$415.80

Market Cap

3.11M

Avg. Volume

10.67K

Dividend Yield

Financial Metrics & Statements of Decoy Therapeutics Inc (DCOY)

FAQ's for Decoy Therapeutics Inc (DCOY)

According to Musaffa’s Shariah screening methodology, Decoy Therapeutics Inc (DCOY) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.